Last update 18 Apr 2025

Tvardi Therapeutics, Inc.

Public Company|
2017|
Texas, United States
|
tvarditherapeutics.com

Overview

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
STAT3(Signal transducer and activator of transcription 3)2

Related

2
Drugs associated with Tvardi Therapeutics, Inc.
C-188-9
Target
STAT3
Mechanism
STAT3 inhibitors
Active Org.
Tvardi Therapeutics, Inc. (Old)Tvardi Therapeutics, Inc. (Old)Startup [+4]
Originator Org.
Baylor College of MedicineBaylor College of Medicine
Active Indication
Idiopathic Pulmonary Fibrosis [+13]
Inactive Indication
Advanced breast cancer [+6]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
TTI-109
Target
STAT3
Mechanism
STAT3 inhibitors
Active Org.
Tvardi Therapeutics, Inc. (Old)Tvardi Therapeutics, Inc. (Old)Startup
Originator Org.
Tvardi Therapeutics, Inc. (Old)Tvardi Therapeutics, Inc. (Old)Startup
Active Indication-
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
8
Clinical Trials associated with Tvardi Therapeutics, Inc.
NCT05668949
/ Not yet recruitingPhase 1/2IIT
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT05845307
/ Not yet recruitingEarly Phase 1IIT
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
NCT06141031
/ SuspendedPhase 1/2IIT
Phase 1/2 Trial of Radiotherapy in Combination with TTI-101 in Patients with Borderline Resectable Pancreatic Cancer
100 Clinical Results associated with Tvardi Therapeutics, Inc.
Login to view more data
0 Patents (Medical) associated with Tvardi Therapeutics, Inc.
Login to view more data
100 Deals associated with Tvardi Therapeutics, Inc.
Login to view more data
100 Translational Medicine associated with Tvardi Therapeutics, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Phase 2
Other
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
C-188-9
 ( STAT3 )		Non-Small Cell Lung Cancer
More
Phase 1
CR-859
 ( CB2 )		Neuralgia
More
Discontinued
CR-701
 ( CB1R x CB2 )		Neuralgia
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free